Journal of Clinical Oncology, Vol 16, 3509-3517, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer

BW Cooper, TJ Moss, AA Ross, J Ybanez and HM Lazarus
Department of Medicine, Ireland Cancer Center, Case Western Reserve University, Cleveland, OH 44106, USA. bxc12@po.cwru.edu

PURPOSE: To determine whether occult tumor contamination of autologous bone marrow or peripheral-blood progenitor cells (PBPC) influences clinical outcome after high-dose chemotherapy in patients with stage IV breast cancer. PATIENTS AND METHODS: We used an immunocytochemical assay capable of detecting one tumor cell in 5 x 10(5) hematopoietic cells to analyze bone marrow and/or PBPC collections obtained from 57 consecutive women with chemotherapy-sensitive metastatic breast cancer who received high-dose chemotherapy. The influence of occult tumor on time to progression, overall survival, and first site of recurrence (old or new) was studied. RESULTS: Twenty-three of 57 (40%) patients received bone marrow (n=6) or peripheral-blood progenitor collections (n=17) that contained microscopic cancer. Median time to progression and overall survival were 9 and 22 months in patients who did not receive infused tumor cells, compared with 10 and 24 months, respectively, in those who received occult tumor (P=not significant [NS]). Worse survival, but not time to progression, was observed in six patients who received > or = 2/100,000 tumor cells. Regardless of whether occult tumor was infused, the majority of relapses occurred in prior, rather than new sites of disease. Three patients who received stem-cell products contaminated by microscopic breast cancer remain free from progression at 21+, 47+, and 52+ months. CONCLUSION: Microscopic tumor was frequently detected by immunocytochemistry in hematopoietic stem-cell products, but did not predict for inferior treatment outcome in this cohort of patients with metastatic breast cancer. Quantitative information regarding infused tumor burden may have prognostic significance.

This article has been cited by other articles:

				M. Quintela-Fandino, J. M. Lopez, R. Hitt, S. Gamarra, A. Jimeno, R. Ayala, J. Hornedo, C. Guzman, F. Gilsanz, and H. Cortes-Funes Breast Cancer-Specific mRNA Transcripts Presence in Peripheral Blood After Adjuvant Chemotherapy Predicts Poor Survival Among High-Risk Breast Cancer Patients Treated With High-Dose Chemotherapy With Peripheral Blood Stem Cell Support J. Clin. Oncol., August 1, 2006; 24(22): 3611 - 3618. [Abstract] [Full Text] [PDF]

				C. M. Thirukkumaran, J. M. Luider, D. A. Stewart, T. Cheng, S. M. Lupichuk, M. J. Nodwell, J. A. Russell, I. A. Auer, and D. G. Morris Reovirus oncolysis as a novel purging strategy for autologous stem cell transplantation Blood, July 1, 2003; 102(1): 377 - 387. [Abstract] [Full Text] [PDF]

				T. E. Witzig, B. Bossy, T. Kimlinger, P. C. Roche, J. N. Ingle, C. Grant, J. Donohue, V. J. Suman, D. Harrington, J. Torre-Bueno, et al. Detection of Circulating Cytokeratin-positive Cells in the Blood of Breast Cancer Patients Using Immunomagnetic Enrichment and Digital Microscopy Clin. Cancer Res., May 1, 2002; 8(5): 1085 - 1091. [Abstract] [Full Text] [PDF]

				S. Kasimir-Bauer, S. Mayer, P. Bojko, D. Borquez, R. Neumann, and S. Seeber Survival of Tumor Cells in Stem Cell Preparations and Bone Marrow of Patients with High-Risk or Metastatic Breast Cancer after Receiving Dose-intensive or High-Dose Chemotherapy Clin. Cancer Res., June 1, 2001; 7(6): 1582 - 1589. [Abstract] [Full Text] [PDF]

				A. Wu, A. Mazumder, R. L. Martuza, X. Liu, M. Thein, K. R. Meehan, and S. D. Rabkin Biological Purging of Breast Cancer Cells Using an Attenuated Replication-competent Herpes Simplex Virus in Human Hematopoietic Stem Cell Transplantation Cancer Res., April 1, 2001; 61(7): 3009 - 3015. [Abstract] [Full Text]

				A. Schneeweiss, M. Hensel, R. Goerner, T. Khbeis, S. Hohaus, G. Egerer, E. Solomayer, R. Haas, E.-M. Grischke, G. Bastert, et al. Comparison of Double and Triple High-Dose Chemotherapy with Autologous Blood Stem Cell Transplantation in Patients with Metastatic Breast Cancer Stem Cells, February 1, 2001; 19(2): 151 - 160. [Abstract] [Full Text]

				H. Ozer, J. O. Armitage, C. L. Bennett, J. Crawford, G. D. Demetri, P. A. Pizzo, C. A. Schiffer, T. J. Smith, G. Somlo, J. C. Wade, et al. 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines J. Clin. Oncol., October 20, 2000; 18(20): 3558 - 3585. [Full Text] [PDF]

				R. Sabbatini, M. Federico, M. Morselli, R. Depenni, K. Cagossi, M. Luppi, G. Torelli, and V. Silingardi Detection of Circulating Tumor Cells by Reverse Transcriptase Polymerase Chain Reaction of Maspin in Patients With Breast Cancer Undergoing Conventional-Dose Chemotherapy J. Clin. Oncol., May 9, 2000; 18(9): 1914 - 1920. [Abstract] [Full Text] [PDF]